Ogrinc F G, Linet O I
Upjohn Company, Kalamazoo, Michigan, USA.
J Urol. 1995 Oct;154(4):1356-9.
The clinical assessment of pharmacologically induced erectile response was compared to the real-time RigiScan* monitoring response.
Erection was induced by 521 intracavernous injections of a new alprostadil formulation. The clinical end point was "full rigidity" and the RigiScan criterion was radial rigidity of 70% or more for 10 consecutive minutes or longer.
For 752 prostaglandin E1 injections the sensitivity and specificity of the RigiScan device compared to clinical evaluation were 53.8% (133 of 247 cases) and 92.9% (469 of 505), respectively. For rigidity of 60% or greater the sensitivity increased to 70.8% (175 of 247 cases) and specificity decreased to 85.0% (429 of 505).
The RigiScan device is useful to document objectively a pharmacologically induced erection yet it appears to be more conservative than clinical evaluation.
将药物诱导勃起反应的临床评估与实时RigiScan*监测反应进行比较。
通过521次海绵体内注射一种新的前列地尔制剂诱导勃起。临床终点为“完全勃起”，RigiScan标准为连续10分钟或更长时间径向硬度达到70%或更高。
对于752次前列腺素E1注射，与临床评估相比，RigiScan设备的敏感性和特异性分别为53.8%（247例中的133例）和92.9%（505例中的469例）。对于硬度达到60%或更高的情况，敏感性增至70.8%（247例中的175例），特异性降至85.0%（505例中的429例）。
RigiScan设备有助于客观记录药物诱导的勃起，但它似乎比临床评估更为保守。
